DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CUBICIN RF

« Back to Dashboard

Clinical Trials for Cubicin Rf

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00295178	Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas	Completed	Cubist Pharmaceuticals LLC	Phase 4	This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: - Time to erythema margin cessation to progress - Time to defervescence - Time to hospital discharge following relief of the presenting cellulitis or erysipelas - Degree of improvement of the following signs and symptom of cellulitis or erysipelas including - Degree of improvement of cellulitis-related pain and swelling as reported by subjects Additionally, the difference in frequency of Adverse Events between daptomycin and vancomycin will be described.
NCT00638157	Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)	Terminated	Cubist Pharmaceuticals LLC	Phase 4	multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
NCT00651131	Cubicin(R) for Complicated Post-Surgical Wound Infections	Terminated	Cubist Pharmaceuticals LLC	Phase 4	The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections
NCT00772447	China Registration Study in Patients With Skin Infections	Completed	AstraZeneca	Phase 3	The objectives of this study is to evaluate the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared with that of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects with Complicated Bacterial Skin and Skin Structure Infection due to Gram-Positive Pathogens.
NCT01012089	Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease	Completed	Cubist Pharmaceuticals LLC	N/A	The purpose of this study is to: 1. Study the pharmacokinetics and safety of daptomycin in children on hemodialysis (HD) and peritoneal dialysis (PD). 2. Determine urine, HD and PD clearance of daptomycin.

Clinical Trial Conditions for Cubicin Rf

Condition Name

Condition Name for Cubicin Rf
Intervention	Trials
Gram Positive Bacteria	1
Wound Infections	1
Critical Care	1
Skin Diseases	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cubicin Rf
Intervention	Trials
Infection	2
Communicable Diseases	2
Soft Tissue Infections	1
Endocarditis, Bacterial	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cubicin Rf

Trials by Country

Trials by Country for Cubicin Rf
Location	Trials
China	9
United States	9
France	1
Switzerland	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cubicin Rf
Location	Trials
Pennsylvania	2
Michigan	2
Texas	1
Minnesota	1
Oklahoma	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cubicin Rf

Clinical Trial Phase

Clinical Trial Phase for Cubicin Rf
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	2
Phase 1	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cubicin Rf
Clinical Trial Phase	Trials
Completed	4
Terminated	3
Recruiting	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cubicin Rf

Sponsor Name

Sponsor Name for Cubicin Rf
Sponsor	Trials
Cubist Pharmaceuticals LLC	5
University Hospital Inselspital, Berne	1
University of Oklahoma	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cubicin Rf
Sponsor	Trials
Industry	6
Other	3

Export unavailable in trial.
Subscribe for complete access.